• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vox Sang . Rates of severe acute respiratory syndrome coronavirus 2 infection in a highly exposed South African blood donor cohort, 2022-2023

tetano

Editor, Senior Moderator
Vox Sang

. 2026 Sep 25.
doi: 10.1111/vox.70368. Online ahead of print.

Rates of severe acute respiratory syndrome coronavirus 2 infection in a highly exposed South African blood donor cohort, 2022-2023​


Marion Vermeulen 1 2 , Ronel Swanevelder 1 , Cordelia Mmenu 1 , Tinus Brits 1 , Josephine Mitchel 1 , Eduard Grebe 3 4 5

Affiliations Expand


Abstract​


Background and objectives: A cohort of South African repeat blood donors was established to leverage the repeated presentation of blood donors for longitudinal serological surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and reinfection incidence in a highly exposed population.


Materials and methods: The prospective cohort was followed from January 2022 to December 2023, with a total of 7459 blood samples from 2155 donors captured and tested using the Roche anti-nucleocapsid (N) and anti-spike (S) total immunoglobulin antibody (Ab) assays. First infections were identified by anti-N seroconversion and reinfections by anti-N boosting (≥1.5-fold) in longitudinal testing, using a novel method to reduce misclassification from prolonged Ab maturation. Incidence was estimated, and correlates of infection were assessed using multivariable Cox proportional hazards regression.


Results: A total of 948 infection events were observed during the study period-280 first infections and 668 reinfections, with up to 4 serial infection events in one donor. Total infection incidence was estimated at 64.2 infections/100 person-years (95% confidence interval [CI]: 60.2-68.4). In multivariable models, quartile of anti-N reactivity was a strong correlate of protection against reinfection with an adjusted hazard ratio of 0.26 (95% CI: 0.18-0.38).


Conclusion: Longitudinal blood donor serosurveillance allowed quantification of continuing SARS-CoV-2 transmission after most individuals had been previously infected in the 2 years after relaxation of non-pharmaceutical interventions.

Keywords: SARS‐CoV‐2; blood donor cohort; incidence; reinfection; seroepidemiology.
 
Back
Top Bottom